BMJ reports US trial will test semaglutide's effect on criminal behaviour
The planned study extends incretin research beyond metabolic endpoints into behavioural and criminal-justice outcomes.
PR
By Priya Raman · Science Reporter
Oct 19 20:00 ETSource: BMJ (Clinical research ed.)
The wire
- 01The BMJ reports that a US trial will test whether semaglutide reduces criminality, extending GLP-1 research into behavioural outcomes.
- 02Clinicians and operators tracking off-label and investigational GLP-1 uses should note that behavioural endpoints are entering formal trial design.
- 03Trial size, population, comparator and funding details are not set out in the report, and no results exist yet.
From the source
Read at pubmed.ncbi.nlm.nih.govGLP-1s and criminality: US trial will test whether semaglutide can fight crime
BMJ (Clinical research ed.) · 2026 Oct 20 · Taylor L et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42901618/
